1000
Asia Pacific J Clin Nutr (1996) 5(1): 53-56
Asia Pacific J Clin
Nutr (1996) 5(1): 53-56
Probiotics
and stabilisation of the gut mucosal barrier
Salminen S1, Isolauri E2, Salminen
E3
1 Dept of Biochemistry and Food Chemistry,
University of Turku, Finland and Key Centre for Applied and Nutritional
Toxicology, RMIT, Melbourne, Australia
2 Dept of Medicine, University of Tampere, Finland
3 Dept of Oncology and Radiotherapy, Turku University Hospital, Turku,
Finland
Probiotic bacteria are used to treat disturbed
intestinal microflora and altered gut permeability which are characteristic
to many intestinal disorders. Examples include children with acute
rotavirus diarrhoea, subjects with food allergy and patients undergoing
pelvic radiotherapy. Altered intestinal microflora has been treated
by oral intake of probiotic bacteria which are able to survive
gastric conditions, colonise the intestine, at least temporarily,
by adhering to the intestinal epithelium. Such probiotic microorganisms
appear to be promising candidates for the treatment of clinical
conditions with abnormal gut microflora and altered gut mucosal
barrier functions.
Introduction
The intestinal epithelium and the normal intestinal
microflora represent a barrier to the movement of pathogenic bacteria,
antigens and other noxious substances from the gut lumen. Under normal
circumstances this barrier is intact and provides normal intestinal
function. When either the epithelial cells or the normal microflora
are disturbed altered permeability facilitates the invasion of pathogens,
foreign antigens and other harmful substances. For future clinical
applications and the development of new probiotic bacteria understanding
of the mechanisms of this barrier system are essential.
Mucosal and
microflora defects and disease
Intestinal
barrier
The intestinal mucosa is an important organ of defence
providing a barrier against the antigens encountered by the enteric
route, and most foreign antigens are excluded by the intestines
mucosal barrier.1 Apart from the barrier function, the
intestinal mucosa is efficient in assimilating antigens. For this
purpose, there are specialised antigen transport mechanisms in the
villous epithelium and particularly in Peyers patches, essential
for evoking specific immune responses.2
Even in physiological conditions, a quantitatively
nonimportant but immunologically important fraction of antigens bypasses
the defence barrier. They are absorbed across the epithelial layer
by transcytosis along two functional pathways.2 The main
degradative pathway entails lysosomal processing of the protein to
smaller peptide fragments which reduces immunogenicity of the protein
and is important in host-de 1000 fence in diminishing the antigen
load. More than 90% of the protein internalised passes in this way.
A minor pathway allows the transport of intact proteins which results
in antigen-specific immune responses. In health paracellular leakage
of macromolecules is not allowed due to intact intercellular tight
junctions maintaining the macromolecular barrier. The integrity of
the defence barrier is necessary to prevent inappropriate and uncontrolled
antigen transport.
Intestinal antigen handling determines subsequent
immune response to the antigen. These include immune exclusion of
antigens encountered by the enteric route by interfering with the
adherence of antigens, immune elimination of substances that have
penetrated the mucosa, and immune regulation of the systemic immune
response to antigen-specific systemic hyporesponsiveness.3
There is evidence that during the absorption process across the intestinal
mucosa, antigens are altered into tolerogenic form.4
Immature
gut defence barrier
The barrier functions are incompletely developed in
early infancy. Intestinal permeability can be transiently increased
postnatally, particularly in premature infants.5,6 The
binding of antigens to immature gut microvillus membrane is increased
compared to the mature mucosa, which has been shown to correlate with
the increased uptake of intact macromolecules.7 An increased
antigen load may evoke aberrant immune responses and lead to sensitisation.8
Intestinal
inflammation
As a result of local intestinal inflammation, a greater
amount of antigens may traverse the mucosal barrier and the routes
of transport are altered.9 Aberrant antigen transport results
in overriding the normal tolerogenic signal into an immunogenic stimulus
favouring allergic reactions.10,11 Foreign antigens such
as viruses, bacteria or dietary antigens can induce local inflammation
in the intestinal mucosa.
Acute
gastroenteritis
Rotavirus is the most common cause of acute childhood
diarrhoea worldwide.12 Rotaviruses invade the highly differentiated
absorptive columnar cells of the small intestinal epithelium, where
they replicate. Partial disruption of the intestinal mucosa ensues
with loss of microvilli and decrease in the villus/crypt ratio. Rotavirus
infection has been shown to be associated with increased intestinal
permeability.13 Moreover, the levels of immune complexes
containing dietary b -lactoglobulin in sera were
significantly higher in patients with rotavirus diarrhoea than in
nondiarrhoeal patients. Macromolecular absorption has also been shown
to be increased in rotavirus gastoenteritis.13-16 The intestinal
microflora affects gut permeability, so that in the absence of intestinal
microflora, disturbance in intestinal absorption of macromolecules
is more severe than in its presence.
Food
allergy
Food allergy is defined as an immunologically mediated
adverse reaction against dietary antigens. The immaturity of the immune
system and the gastrointestinal barrier may explain the peak prevalence
of food allergies in infancy.17 In food allergy, intestinal
inflammation18 and disturbances in intestinal permeability19
and antigen transfer20 occur when an allergen comes into
contact with the intestinal mucosa. During dietary elimination of
the antigen, the barrier and transfe 1000 r functions of the mucosa
are normal.18-20 It has therefore been concluded that impairment
of the intestines function is secondary to an abnormal intestinal
immune response to the offending antigens.
Atopic
dermatitis
Atopic dermatitis is a common and complex, chronically
relapsing skin disorder of infancy and childhood. Hereditary predisposition
is an important denominator of atopic dermatitis, and hypersensitivity
reactions contribute the expression of this predisposition.21
The relationship between environmental allergens and exacerbation
of atopic dermatitis is particularly apparent in infancy so that dietary
antigens predominate and allergic reactions to foods are common.17
In a recent study,22 macromolecular absorption
across the intestinal mucosa was assessed in vitro in children
(aged 0.5-8 years) with atopic dermatitis. In these patients, the
offending foods were identified and eliminated, and the intestinal
mucosa was not challenged in vitro nor in vivo. Significantly
increased absorption of protein, in intact and degraded form, was
found in the atopic dermatitis patients compared to controls. The
result may reflect a primarily altered antigen transfer in atopic
dermatitis. Aberrant antigen absorption could partly explain why patients
with atopic dermatitis frequently show heightened immune responses
to common environmental antigens, including dietary antigens.
Crohns
disease
Crohns disease is a chronic and idiopathic inflammation
of the gastrointestinal tract with characteristic patchy transmural
lesions containing granulomas. The outbreak of Crohns disease
is thought to require genetic predisposition, immunologic disturbance
and the influence of intraluminal triggering agent(s), for example
bacteria or viruses. Crohns disease is associated with impairment
of the barrier function. In a recent in vitro study,23
a rise in macromolecular absorption in uninvolved parts of the intestine
was detected in patients with clinically moderate or severe Crohns
disease. An interplay between the immune effector cells and the intestinal
vascular endothelium has been suggested to result in disrupted vasculature,
cell-mediated immunity with lymphokine production and a vigorous IgG
response and finally dysfunction of the mucosa.24,25
Figure 1.
Changes during intestinal disorders
and potential targets of treatment and prevention.
|
Pelvic radiotherapy
Radiotherapy has a profound effect on the intestinal mucosa and
the highly proliferative tissue. Radiation creates changes in bacterial
flora, vascular permeability of the mucosa and intestinal motility.26,27
The villi retract and shorten within a few days from the beginning
of the treatment and total disappearance may result.26,27
The result is a flat surface covered by thin columnar epithelial cells
which may also be lost leading to ulcerated surface. Within three
to ten days the intestinal epithelium may be completely denuded and
the villous surface is replaced by a layer of exudate in which masses
of bacteria are present. Bacteria can penetrate the damaged villi
leading to bacteraemia in extreme cases.26,27 The reasons
for radiation enteropathy in man include both damage to intestinal
mucosa, changes in the intestinal microflora and impaired immune response
(Figure 1< 1000 /a>).
Clinically, the primary
reactions start during early weeks of treatment giving such symptoms
as nausea, vomiting and diarrhoea. The late secondary reaction, eg,
fibrosis and obstruction of the intestine, may give clinical symptoms
years after. The relationship between early and late reactions is
not clear, although some studies have indicated that the severe early
reactions precede serious late effects.27,28 Lactobacillus
supplementation in lethally irradiated mice has been reported to prolong
their survival.29
Future developments
Probiotic bacteria (eg, Bifidobacterium bifidum
and Lactobacillus GG) have beneficial effects on the clinical
course of rotavirus diarrhoea.30-32 In a similar manner,
Lactobacillus acidophilus preparations and Lactobacillus
casei preparations have been beneficial in the prevention of
radiation enteropathy.33-35 Among the possible mechanisms
responsible for the favourable clinical response is promotion of the
immunologic and nonimmunologic defence barrier in the gut.
Oral introduction of Lactobacillus GG has been
associated with alleviation of intestinal inflammation and normalisation
of increased intestinal permeability36 and gut microflora.37
Another explanation for the gut-stabilising effect of Lactobacillus
GG could be improvement of the intestines immunologic barrier,
particularly intestinal IgA responses.36
Important
properties for probiotic bacteria
The most important properties for future probiotics
include the acid and bile tolerance, adherence to human intestinal
mucosa, temporary colonisation of the human gastrointestinal tract,
production of antimicrobial substances and inhibition of pathogen
growth.38 It is also important that the strains used are
of human origin since many of the properties may be species dependent.
Probiotic bacteria with these properties and documented clinical effects
include Lactobacillus acidophilus NCFB 1748, Lactobacillus
casei Shirota strain, Lactobacillus GG and Lactobacillus
acidophilus LA1.38 All of these are also currently
further tested for difference intestinal problems and offer alternatives
for dietary treatment of intestinal disorders. In the future, it is
likely that we shall see more specific clinical targets for probiotic
therapy and then the above mentioned strains are likely to play an
important role in new products.
Conclusion
These results taken together indicate that probiotic
bacteria appear promising candidates for the treatment of clinical
conditions with altered gut mucosal barrier functions. Probiotic bacteria
may stabilise the intestinal microflora and they can be used for immunotherapy
to counteract immunological dysfunction and to stabilise the gut mucosal
barrier to strengthen endogenous defence mechanisms.
Chinese abstract
References
- Sanderson IR, Walker WA: Uptake and 1000 transport
of macromolecules by the intestine: possible role in clinical disorders
(an update). Gastroenterology 1993; 104: 622-639.
- Heyman M, Ducroc R, Desjeux JF and Morgat JL. Horseradish
peroxidase transport across adult rabbit jejunum in vitro. Am J
Physiol 1982; 242: G558-G564.
- Strobel S. Mechanisms of gastrointestinal immunoregulation
and food induced injury. Eur J Clin Nutr 1991; 45: 1-9.
- Bruce MG and Ferguson A. The influence of intestinal
processing on the immunogenicity and molecular size of absorbed,
circulating ovalbumin in mice. Immunology 1986; 59: 295-300.
- Beach RC, Menzies IS, Clayden GS and Scopes JW.
Gastrointestinal permeability changes in the preterm neonate. Arch
Dis Child 1982; 57: 141-5.
- Axelsson I, Jakobsson I, Lindberg T, Polberger
S, Benediktsson B and Raiha N. Macromolecular absorption in preterm
and term infants. Acta Paediatr Scand 1989; 78: 532-7.
- Stern M, Pang KY and Walker WA. Food proteins and
gut mucosal barrier. II. Differential interaction of cows
milk proteins with the mucous coat and the surface membrane of adult
and immature rat jejunum. Pediatr Res 1984; 18: 1252-7.
- Holt PG, McMenamin C and Nelson D. Primary sensitisation
to inhalant allergens during infancy. Pediatr Allergy Immunol 1990;
1: 3-13.
- Heyman M and Desjeux JF. Significance of intestinal
food protein transport. J Pediatr Gastroenterol Nutr 1992; 15: 48-57.
- Holt PG. Immunoprophylaxis of atopy: light at the
end of the tunnel. Immunol Today 1994; 15: 484-9.
- Fargeas MJ, Theodorou V, More J, Wal JM, Fioramonti
J and Bueno L. Boosted systemic immune and local responsiveness
after intestinal inflammation in orally sensitized guinea pigs.
Gastroenterology 1995; 109: 53-62.
- Claeson M, Merson MH. Global progress in the control
of diarrheal disease. Pediatr Infect Dis 1990; 9: 345-55.
- Jalonen T, Isolauri E, Heyman M, Crain-Denoyelle
A-M, Sillanaukee P and Koivula T. Increased b -lactoglobulin absorption during rotavirus enteritis in infants:
relationship to sugar permeability. Pediatr Res 1991; 30: 290-3.
- Heyman M, Gorthier G, Petit A, Meslin J-C, Moreau
C and Desjeux J-F. Intestinal absorption of macromolecules during
viral enteritis: an experimental study on rotavirus infected conventional
and germ-free mice. Pediatr Res 1987; 22: 72-8.
- Uhnoo IS, Freihorst J, Riepenhoff-Talty M, Fisher
JE and Ogra PL. Effect of rotavirus infection and malnutrition on
uptake of a dietary antigen in the intestine. Pediatr Res 1990;
27: 153-160.
- Isolauri E, Kaila M, Arvola T, Majamaa H, Rantala
I, Virtanen E and Arvilommi H. Diet during rotavirus enteritis affects
jejunal permeability to macromolecules in suckling rats. Pediatr
Res 1993; 33: 548-53.
- Isolauri E and Turjanmaa K. Combined skin prick
and patch testing enhances identification of food allergy in infants
with atopic dermatitis. J Allergy Clin Immunol 1995 (in press).
- Majamaa H, Miettinen A, Laine S, Isolauri E. Intestinal
inflammation in children with atopic eczema: 1000 faecal eosinophil
cationic protein and tumour necrosis factor-a as noninvasive indicators
of food allergy. Clin Exp Allergy 1995 (in press).
- Jalonen T. Identical intestinal permeability changes
in children with different clinical manifestations of cows
milk allergy. J Allergy Clin Immunol 1991; 88: 737-42.
- Heyman M, Grasset E, Ducroc R and Desjeux JF. Antigen
absorption by the jejunal epithelium of children with cows
milk allergy. Pediatr Res 1988; 24: 197-202.
- Sampson HA and McCaskill CC. Food hypersensitivity
and atopic dermatitis: evaluation of 113 patients. J Pediatr 1985;
107: 669-75.
- Majamaa H, Isolauri E. Evaluation of the gut mucosal
barrier: evidence for increased antigen transfer in children with
atopic eczema. J Allergy Clin Immunol 1995 (in press).
- Isolauri E. Intestinal integrity and IBD. Kluwer
Academic Publishers, Lancaster, UK, 1995: 85: 553-5.
- Podolsky DK: Inflammatory bowel disease. (First
of two parts). New Engl J Med 1991; 325: 928-937.
- MacDonald TT: Aetiology of Crohns disease.
Arch Dis Child 1993; 68: 623-625.
- Friberg L-G. Effects of irradiation on the small
intestine of the rat. a SEM study. Ph.D. Thesis, University of Lund,
Lund, Sweden.
- Silva C. The use of elemental diets in radiation
enteritis. Bounous G, ed., Uses of elemental diets in clinical situations.
CRC Press, Boca Raton, FL, USA: 122-134.
- Dahl O, Horn A, Mella O. Do acute side effects
during radiotherapy predict tumour response in rectal carcinoma.
Acta Oncol 1994; 33: 409-413.
- Dong M-Y, Chang T-W, Gorbach SL. Effects of feeding
Lactobacillus GG on lethal irradiation in mice. Diagn Microbiol
Infect Dis 1987; 7: 1-7.
- Isolauri E, Juntunen M, Rautanen T, Sillanaukee
P, Koivula T. A human Lactobacillus strain (Lactobacillus
GG) promotes recovery from acute diarrhea in children. Pediatrics
1991; 88: 90-7.
- Kaila M, Isolauri E, Soppi E, Virtanen E, Laine
S, Arvilommi H. Enhancement of the circulating antibody secreting
cell response in human diarrhea by a human lactobacillus
strain. Pediatr Res 1992; 32: 141-44.
- Saavedra JM, Bauman N, Oung I, Perman J, Yolken
R. Feeding of Bifidobacterium bifidum and Streptococcus
thermophilus to infants in hospital for prevention of diarrhoea
and shedding of rotavirus. The Lancet l994; 344: 1046-1049.
- Salminen E, Elomaa I, Minkkinen J, Vapaatalo H,
Salminen S. Preservation of intestinal integrity during radiotherapy
using live Lactobacillus acidophilus cultures. Clin Radiol
1988; 39: 435-437.
- Salminen E, Salminen S, Vapaatalo H, Holsti LR.
Adverse effects of pelvic radiotherapy. International Meeting on
Progress in Radio-oncology, HD Kogelnik ed., Monduzzi Editore, Italy
1995: 501-504.
- Okawa T, Niibe H, Arai T, Sekiba K, Noda K, Takeuchi
S, Hashimoto S, Ogawa N. Effect of LC9018 combined with radiation
therapy on carcinoma of the uterine cervix. Cancer 1993; 72: 1949-1954.
- Isolauri E, Majamaa H, Arvola T, Rantala I, Virtanen
E, Arvilommi H. Lactobacillus casei 4c4 strain GG reverses
increased intestinal permeability induced by cow milk in suckling
rats. Gastroenterology 1993; 105: 1643-50.
- Isolauri E, Kaila M, Mykkanen H, Ling WH and Salminen
S. Oral bacteriotherapy for viral gastroenteritis. Dig Dis Sci 1994;
39: 2595-2600.
- Lee Y-K, Salminen S. The coming of age of probiotics.
Trends in Food Sci Techn 1995; 6: 241-245.
Copyright © 1996 [Asia Pacific Journal of Clinical
Nutrition]. All rights reserved.
Revised:
January 19, 1999
.
0